These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 3617160

  • 1. Spironolactone as a source of interference in commercial digoxin immunoassays.
    Morris RG, Lagnado PY, Lehmann DR, Frewin DB, Glistak ML, Burnet RB.
    Ther Drug Monit; 1987 Jun; 9(2):208-11. PubMed ID: 3617160
    [Abstract] [Full Text] [Related]

  • 2. Reassessment of cross-reactivity of spironolactone metabolites with four digoxin immunoassays.
    Pleasants RA, Williams DM, Porter RS, Gadsden RH.
    Ther Drug Monit; 1989 Jun; 11(2):200-4. PubMed ID: 2655203
    [Abstract] [Full Text] [Related]

  • 3. The effect of renal and hepatic impairment and of spironolactone on digoxin immunoassays.
    Morris RG, Frewin DB, Taylor WB, Glistak ML, Lehmann DR.
    Eur J Clin Pharmacol; 1988 Jun; 34(3):233-9. PubMed ID: 3396618
    [Abstract] [Full Text] [Related]

  • 4. Influence of spironolactone and its metabolite canrenone on serum digoxin assays.
    Foukaridis GN.
    Ther Drug Monit; 1990 Jan; 12(1):82-4. PubMed ID: 2305425
    [Abstract] [Full Text] [Related]

  • 5. Spironolactone-associated digoxin radioimmunoassay interference.
    Silber B, Sheiner LB, Powers JL, Winter ME, Sadée W.
    Clin Chem; 1979 Jan; 25(1):48-50. PubMed ID: 761378
    [Abstract] [Full Text] [Related]

  • 6. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
    Dasgupta A, Tso G, Wells A.
    Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
    [Abstract] [Full Text] [Related]

  • 7. Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids.
    Steimer W, Müller C, Eber B.
    Clin Chem; 2002 Mar; 48(3):507-16. PubMed ID: 11861441
    [Abstract] [Full Text] [Related]

  • 8. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
    DeFrance A, Armbruster D, Petty D, Cooper KC, Dasgupta A.
    Ther Drug Monit; 2011 Feb; 33(1):128-31. PubMed ID: 21079546
    [Abstract] [Full Text] [Related]

  • 9. A new turbidometric digoxin immunoassay on the ADVIA 1650 analyzer is free from interference by spironolactone, potassium canrenoate, and their common metabolite canrenone.
    Datta P, Dasgupta A.
    Ther Drug Monit; 2003 Aug; 25(4):478-82. PubMed ID: 12883233
    [Abstract] [Full Text] [Related]

  • 10. Interference between eplerenone and digoxin in fluorescence polarization immunoassay, microparticle enzyme immunoassay, and affinity column-mediated immunoassay.
    Yamada T, Suzuki K, Iguchi K, Kanada Y, Kato R, Ijiri Y, Nishihara M, Murakami S, Hayashi T, Tamai H, Tanaka K.
    Ther Drug Monit; 2010 Dec; 32(6):774-7. PubMed ID: 20625353
    [Abstract] [Full Text] [Related]

  • 11. A critical appraisal of a further three new commercial digoxin radioimmunoassay kits with reference to cross-reacting substances.
    Wood WG, Wachter C.
    J Clin Chem Clin Biochem; 1979 Feb; 17(2):77-83. PubMed ID: 422947
    [Abstract] [Full Text] [Related]

  • 12. Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.
    Dasgupta A, Johnson MJ.
    J Clin Lab Anal; 2010 Feb; 24(6):413-7. PubMed ID: 21089173
    [Abstract] [Full Text] [Related]

  • 13. Cross reactivity of digitoxin and spironolactone in two radioimmunoassays for serum digoxin.
    Müller H, Bräuer H, Resch B.
    Clin Chem; 1978 Apr; 24(4):706-9. PubMed ID: 639280
    [Abstract] [Full Text] [Related]

  • 14. Negligible interference by spironolactone and prednisone in digoxin radioimmunoassay.
    Ravel R.
    Clin Chem; 1975 Nov; 21(12):1801-3. PubMed ID: 1183001
    [Abstract] [Full Text] [Related]

  • 15. A new enzyme-linked chemiluminescent immunosorbent digoxin assay is virtually free from interference of spironolactone, potassium canrenoate, and their common metabolite canrenone.
    Dasgupta A, Kang E, Datta P.
    J Clin Lab Anal; 2006 Nov; 20(5):204-8. PubMed ID: 16960898
    [Abstract] [Full Text] [Related]

  • 16. "Lack of clinically significant interference by spironolactone with the Axsym Digoxin II assay" only applies to low-dose therapy with spironolactone.
    Steimer W.
    Ther Drug Monit; 2003 Aug; 25(4):484-5. PubMed ID: 12883235
    [No Abstract] [Full Text] [Related]

  • 17. Intoxication due to negative canrenone interference in digoxin drug monitoring.
    Steimer W, Müller C, Eber B, Emmanuilidis K.
    Lancet; 1999 Oct 02; 354(9185):1176-7. PubMed ID: 10513714
    [Abstract] [Full Text] [Related]

  • 18. Spironolactone interference with digoxin radioimmunoassay in cirrhotic patients.
    DiPiro JT, Cote JR, DiPiro CR, Bustrack JA.
    Am J Hosp Pharm; 1980 Nov 02; 37(11):1518-21. PubMed ID: 7211855
    [Abstract] [Full Text] [Related]

  • 19. Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.
    Dasgupta A, Johnson MJ, Sengupta TK.
    J Clin Lab Anal; 2012 May 02; 26(3):143-7. PubMed ID: 22628228
    [Abstract] [Full Text] [Related]

  • 20. Quantitation of interference in digoxin immunoassay in renal, hepatic, and diabetic disease.
    Tzou MC, Reuning RH, Sams RA.
    Clin Pharmacol Ther; 1997 Apr 02; 61(4):429-41. PubMed ID: 9129560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.